Application of the lewis acid-lewis base bifunctional asymmetric catalysts to pharmaceutical syntheses: Stereoselective chiral building block syntheses of human immunodeficiency virus (HIV) protease inhibitor and β3- adenergic receptor agonist

Chemical and Pharmaceutical Bulletin

Volumn 51, Issue 6, 2003, Pages 702-709

  Nogami, Hiroyuki ^a   Kanai, Motomu ^b   Shibasaki, Masakatsu ^b  

^a MITSUBISHI CHEMICAL CORPORATION   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Asymmetric catalysis; Bifunctional asymmetric catalyst; Cyanosilylation; Human immunodeficiency virus (HIV) protease inhibitor; 3 adrenergic receptor agonist

Indexed keywords

ATAZANAVIR; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; PROTEINASE INHIBITOR;

ARTICLE; CATALYSIS; CHIRALITY; COLUMN CHROMATOGRAPHY; DRUG ACTIVITY; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS; STEREOCHEMISTRY;

EID: 9144242792     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.51.702     Document Type: Article

References (84)

1. Stinson S. C., Chem. Eng. News, 79, 45-57 (2001).
2. Stinson S. C., Chem. Eng. News, 79, 79-97 (2001).
3. Rouhi A. M., Chem. Eng. News, 80, 43-50 (2002).
4. Beck G., Synlett, 2002, 837-850 (2002).
5. Noyori R., "Asymmetric Catalysis in Organic Synthesis," John Wiley & Sons, New York, 1994.
6. "Comprehensive Asymmetric Catalysis," ed. by Jacobsen E. N., Pfaltz A., Yamamoto H., Springer, Berlin, 1999.
7. Ojima I., "Catalytic Asymmetric Synthesis," Wiley-VCH, New York, 2000.
8. Hamashima Y., Sawada D., Kanai M., Shibasaki M., J. Am. Chem. Soc., 121, 2641-2642 (1999).
9. Hamashima Y., Sawada D., Nogami H., Kanai M., Shibasaki M., Tetrahedron, 57, 805-814 (2001).
10. Shibasaki M., Kanai M., Chem. Pharm. Bull., 49, 511-524 (2001).
11. Shibasaki M., Kanai M., Funabashi K., Chem. Commun., 2002, 1989-1999 (2002).
12. Kanai M., Hamashima Y., Shibasaki M., Tetrahedron Lett., 41, 2405-2409 (2000).
13. Manickam G., Nogami H., Kanai M., Groger H., Shibasaki M., Synlett, 2001, 617-620 (2001).
14. For the synthesis of asymmetric cyanohydrins using chiral catalysts, see ref. 15-20.
15. Hwang C.-D., Hwang D.-R., Uang B.-J., J. Org. Chem., 63, 6762-6763 (1998).
16. Belokon' Y. N., Caveda-Cepas S., Green B., Ikonnikov N. S., Khrustalev V. N., Larichev V. S., Moscalenko M. A., North M., Orizu C., Tararov V. I., Tasinazzo M., Timofeeva G. I., Yashkina L. V., J. Am. Chem. Soc., 121, 3968-3973 (1999).
17. Liang S., Bu X. R., J. Org. Chem., 67, 2702-2704 (2002).
18. North M., Synlett, 1993, 807-820 (1993).
19. Effenberger F., Angew. Chem. Int. Ed. Engl., 33, 1555-1564 (1994).
20. Gregory R. J. H., Chem. Rev., 99, 3649-3682 (1999).
21. Takamura M., Hamashima Y., Usuda H., Kanai M., Shibasaki M., Angew. Chem. Int. Ed. Engl., 39, 1650-1652 (2000).
22. Takamura M., Hamashima Y., Usuda H., Kanai M., Shibasaki M., Chem. Pharm. Bull., 48, 1586-1592 (2000).
23. Sawada D., Shibasaki M., Angew. Chem. Int. Ed. Engl., 39, 209-213 (2000).
24. Sawada D., Kanai M., Shibasaki M., J. Am. Chem. Soc., 122, 10521-10532 (2000).
25. Funabashi K., Ratni H., Kanai M., Shibasaki M., J. Am. Chem. Soc., 123, 10784-10785 (2001).
26. Yabu K., Masumoto S., Yamasaki S., Hamashima Y., Kanai M., Du W., Curran D. P., Shibasaki M., J. Am. Chem. Soc., 123, 9908-9909 (2001).
27. Takamura M., Funabashi K., Kanai M., Shibasaki M., J. Am. Chem. Soc., 123, 6801-6808 (2001).
28. Takamura M., Yanagisawa H., Kanai M., Shibasaki M., Chem. Pharm. Bull., 50, 1118-1121 (2002).
29. Masumoto S., Suzuki M., Kanai M., Shibasaki M., Tetrahedron Lett., 43, 8647-8651 (2002).
30. Atazanavir is also known by the experimental name BMS-232632 or CGP-73547, see ref. 31-33.
31. Bold G., Fässler A., Capraro H.-G., Cozens R., Klimkait T., Lazdins J., Mestan J., Poncioni B., Rosel J., Stover D., Tintelnot-Blomley M., Acemoglu F., Ucci-Stoll K., Wyss D., Lang M., J. Med. Chem., 41, 3387-3401 (1998).
32. Rabasseda X., Silvestre J., Castaner J., Drugs Fut., 24, 375-380 (1999).
33. Xu Z., Singh J., Schwinden M. D., Zheng B., Kissick T. P., Patel B., Humora M. J., Quiroz F., Dong L., Hsieh D.-M., Heikes J. E., Pudipeddi M., Lindrud M. D., Srivastava S. K., Kronenthal D. R., Mueller R. H., Org. Process Res. Dev., 6, 323-328 (2002).
34. Currier J. S., Havlir D. V., Topics in HIV Medicine, 10, 11-17 (2002).
35. Wilkin T. J., Hay C. M., Hogan C. M., Hammer S. M., Topics in HIV Medicine, 10, 18-35 (2002).
36. iPrOH-hexane, see ref. 21, 22.
37. Evans B. E., Rittle K. E., Homnick C. F., Springer J. P., Hirshfield J., Veber D. F., J. Org. Chem., 50, 4615-4625 (1985).
38. Luly J. R., Dellaria J. F., Plattner J. J., Soderquist J. L., Yi N., J. Org. Chem., 52, 1487-1492 (1987).
39. Romeo S., Rich D. H., Tetrahedron Lett., 35, 4939-4942 (1994).
40. Ghosh A. K., Fidanze S., J. Org. Chem., 63, 6146-6152 (1998).
41. For selected examples of the synthesis of bestatin or its components, see ref. 42-48.
42. Suda H., Takita T., Aoyagi T., Umezawa H., J. Antibot., 29, 100-101 (1976).
43. Suda H., Takita T., Aoyagi T., Umezawa H., J. Antibot., 29, 600-601 (1976).
44. Matsuda F., Matsumoto T., Ohsaki M., Ito Y., Terashima S., Chem. Lett., 1990, 723-724 (1990).
45. Matsuda F., Matsumoto T., Ohsaki M., Ito Y., Terashima S., Bull. Chem. Soc. Jpn., 65, 360-365 (1992).
46. Kobayashi Y., Teramoto Y., Kamijo T., Harada H., Ito Y., Terashima S., Tetrahedron, 48, 1853-1868 (1992).
47. Wasserman H. H., Xia M., Petersen A. K., Jorgensen M. R., Curtis E. A., Tetrahedron Lett., 40, 6163-6166 (1999).
48. Bergmeier S. C., Stanchina D. M., J. Org. Chem., 64, 2852-2859 (1999).
49. Corey E. J., Zhang F.-Y., Angew. Chem. Int. Ed. Engl., 38, 1931-1934 (1999).
50. Parkes K. E. B., Bushnell D. J., Crakett P. H., Dunsdon S. J., Freeman A. C., Gunn M. P., Hopkins R. A., Lambert R. W., Martin J. A., Merrett J. H., Redshaw S., Spurden W. C., Thomas G. J., J. Org. Chem., 59, 3656-3664 (1994).
51. Girijavallabhan V. M., Bennett F., Patel N. M., Ganguly A. K., Dasmahapatra B., Butkiewicz N., Hart A., Bioorg. Med. Chem., 2, 1075-1083 (1994).
52. For selected examples of the synthesis of HIV protease inhibitors or their components, see ref. 53-56.
53. Sasai H., Kim W.-S., Suzuki T., Shibasaki M., Mitsuda M., Hasegawa J., Ohashi T., Tetrahedron Lett., 35, 6123-6126 (1994).
54. Shibata N., Katoh T., Terashima S., Tetrahedron Lett., 38, 619-620 (1997).
55. Fässler A., Bold G., Steiner H., Tetrahedron Lett., 39, 4925-4928 (1998).
56. Shibata N., Itoh E., Terashima S., Chem. Pharm. Bull., 46, 733-735 (1998).
57. Reetz M. T., Drewes M. W., Harms K., Reif W., Tetrahedron Lett., 29, 3295-3298 (1988).
58. Reetz M. T., Angew. Chem. Int. Ed. Engl., 30, 1531-1546 (1991).
59. Gu J.-H., Okamoto M., Terada M., Mikami K., Nakai T., Chem. Lett., 1992, 1169-1172 (1992).
60. Ipaktschi J., Heydari A., Chem. Ber., 126, 1905-1912 (1993).
61. Nishizawa R., Saino T., Takita T., Suda H., Aoyagi T., Umezawa H., J. Med. Chem., 20, 510-515 (1977).
62. Andrés J. M., Martinez M. A., Pedrosa R., Pérez-Encabo A., Tetrahedron: Asymmetry, 12, 347-353 (2001).
63. Yuan W., Munoz B., Wong C.-H., Haeggström J. Z., Wetterholm A., Samuelsson B., J. Med. Chem., 36, 211-220 (1993).
64. Munoz B., Giam C.-Z., Wong C.-H., Bioorg. Med. Chem., 2, 1085-1090 (1994).
65. Kang S. H., Ryu D. H., Bioorg. Med. Chem. Lett., 5, 2959-2962 (1995).
66. Hanson G. J., Lindberg T., J. Org. Chem., 50, 5399-5401 (1985).
67. Miyaura N., Suzuki A., Chem. Rev., 95, 2457-2483 (1995).
68. Hassan J., Sevignon M., Gozzi C., Schulz E., Lemaire M., Chem. Rev., 102, 1359-1469 (2002).
69. Kotha S., Lahiri K., Kashinath D., Tetrahedron, 58, 9633-9695 (2002).
70. Indolese A. F., Tetrahedron Lett., 38, 3513-3516 (1997).
71. Saito S., Oh-tani S., Miyaura N., J. Org. Chem., 62, 8024-8030 (1997).
72. Saito S., Sakai M., Miyaura N., Tetrahedron Lett., 37, 2993-2996 (1996).
73. Crociani B., Di Bianca F., Giovenco A., Berton A., J. Organomet. Chem., 323, 123-134 (1987).
74. Mitchell M. B., Wallbank P. J., Tetrahedron Lett., 32, 2273-2276 (1991).
75. Ali N. M., McKillop A., Mitchell M. B., Rebelo R. A., Wallbank P. J., Tetrahedron, 48, 8117-8126 (1992).
76. Littke A. F., Fu G. C., Angew. Chem. Int. Ed. Engl., 41, 4176-4211 (2002).
77. Mathvink R. J., Tolman J. S., Chitty D., Candelore M. R., Cascieri M. A., Colwell L. F., Deng L., Feeney W. P., Forrest M. J., Hom G. J., MacIntyre D. E., Miller R. R., Stearns R. A., Tota L., Wyvratt M. J., Fisher M. H., Weber A. E., J. Med. Chem., 43, 3832-3836 (2000).
78. Emorine L. J., Marullo S., Briend-Sutren M.-M., Patey G., Tate K., Delavier-Klutchko C., Strosberg A. D., Science, 245, 1118-1121 (1989).
79. Kordik C. P., Reitz A. B., J. Med. Chem., 42, 181-201 (1999).
80. When HCN was used as a cyanation reagent, the reaction did not proceed at all. This result suggests that the actual nucleophile is TMSCN, not HCN. MeOH must be immediately converted to MeOTMS and HCN. The formation of MeOTMS was confirmed by NMR.
81. Mai K., Patil G., J. Org. Chem., 51, 3545-3548 (1986).
82. Vachal P., Jacobsen E. N., Org. Lett., 2, 867-870 (2000).
83. Sigman M. S., Vachal P., Jacobsen E. N., Angew. Chem. Int. Ed. Engl., 39, 1279-1281 (2000).
84. Nogami H., Matsunaga S., Kanai M., Shibasaki M., Tetrahedron Lett., 42, 279-283 (2001).